Osmotica Pharmaceuticals PLC (NASDAQ:OSMT)’s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $6.25 and last traded at $6.70, with a volume of 94010 shares trading hands. The stock had previously closed at $7.13.
OSMT has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on Osmotica Pharmaceuticals in a research report on Monday, November 12th. They issued a “buy” rating on the stock. Royal Bank of Canada initiated coverage on Osmotica Pharmaceuticals in a research report on Monday, November 12th. They issued an “outperform” rating and a $17.00 price objective on the stock. Wells Fargo & Co initiated coverage on Osmotica Pharmaceuticals in a research report on Monday, November 12th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Barclays initiated coverage on Osmotica Pharmaceuticals in a research report on Wednesday, November 14th. They issued an “overweight” rating on the stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by WKRB News and is the property of of WKRB News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.wkrb13.com/2018/11/23/osmotica-pharmaceuticals-osmt-sets-new-12-month-low-at-6-25.html.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.
Featured Story: How do candlesticks reflect price movement?
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.